{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:51:00Z","timestamp":1789696260864,"version":"4.0.1"},"reference-count":34,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,12,29]],"date-time":"2010-12-29T00:00:00Z","timestamp":1293580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Paromomycin (PM) is an aminoglycoside antibiotic, first isolated in the 1950s, and approved in 2006 for treatment of visceral leishmaniasis. Although isolated six decades back, sufficient information essential for development of pharmaceutical formulation is not available for PM.<\/jats:p><jats:p>The purpose of this paper was to determine thermal stability and development of new analytical method for formulation development of PM. PM was characterized by thermoanalytical (DSC, TGA, and HSM) and by spectroscopic (FTIR) techniques and these techniques were used to establish thermal stability of PM after heating PM at 100, 110, 120, and 130 \u00b0C for 24 h. Biological activity of these heated samples was also determined by microbiological assay. Subsequently, a simple, rapid and sensitive RP\u2010HPLC method for quantitative determination of PM was developed using pre\u2010column derivatization with 9\u2010fluorenylmethyl chloroformate. The developed method was applied to estimate PM quantitatively in two parenteral dosage forms.<\/jats:p><jats:p>PM was successfully characterized by various stated techniques. These techniques indicated stability of PM for heating up to 120 \u00b0C for 24 h, but when heated at 130 \u00b0C, PM is liable to degradation. This degradation is also observed in microbiological assay where PM lost \u223c30% of its biological activity when heated at 130 \u00b0C for 24 h. New analytical method was developed for PM in the concentration range of 25\u2013200 ng\/ml with intra\u2010day and inter\u2010day variability of &lt; 2%RSD. Characterization techniques were established and stability of PM was determined successfully. Developed analytical method was found sensitive, accurate, and precise for quantification of PM. Copyright \u00a9 2010 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/dta.229","type":"journal-article","created":{"date-parts":[[2010,12,29]],"date-time":"2010-12-29T06:55:22Z","timestamp":1293605722000},"page":"363-372","source":"Crossref","is-referenced-by-count":14,"title":["Characterization, thermal stability studies, and analytical method development of Paromomycin for formulation development"],"prefix":"10.1002","volume":"3","author":[{"given":"Wahid","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,29]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"331","article-title":"Visceral leishmaniasis (kala\u2010azar): challenges ahead","volume":"123","author":"Singh R. K.","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2004.07.002"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066536"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2008.09.008"},{"key":"e_1_2_6_6_2","first-page":"489","article-title":"Tetany in kala azar patients treated with paromomycin","volume":"127","author":"Thakur C. P.","year":"2008","journal-title":"Indian J. Med. Res."},{"key":"e_1_2_6_7_2","article-title":"Drug targeting to macrophages using paromomycin loaded albumin microspheres for treatment of visceral leishmaniasis: an in vitro evaluation","author":"Khan W.","year":"2010","journal-title":"J. Drug Target."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0142-9612(00)00074-0"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2009.06.004"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2003.10.041"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/dta.41"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1081\/DDC-120030423"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01319-08"},{"key":"e_1_2_6_14_2","unstructured":"Anonymous. A New Antibiotic Paromomycin.The Patent office1960 Vol. GB797568 pp. 1."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(96)01902-4"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)00133-X"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.23.464"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac60295a003"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(97)00192-8"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1039\/b005253l"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.snb.2006.11.041"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(04)01570-5"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2008.09.026"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2008.08.033"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22173"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2004.02.027"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/dta.153"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/dta.126"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1021\/js970419w"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1128\/AAC.41.5.982","article-title":"Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects","volume":"41","author":"Kanyok T. P.","year":"1997","journal-title":"Antimicrob Agents Ch."},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(95)00355-X"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(97)00032-7"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.farmac.2004.06.002"},{"key":"e_1_2_6_34_2","unstructured":"N.Ali A.Banerjee.A synergistic formulation useful for treatment of leishmaniasis.Indian Patent Application Publication2009 pp.1."},{"key":"e_1_2_6_35_2","unstructured":"G. N.Shankar H. J.Parish.Orally\u2010absorbed formulation for paromomycin.United States Patent Application2008 pp.1."}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.229","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:41:55Z","timestamp":1760362915000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,29]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1002\/dta.229"],"URL":"https:\/\/doi.org\/10.1002\/dta.229","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,29]]}}}